ストックスクリーナーアプリを入手
9.70
1.12%
-0.11
アフターアワーズ：
9.70
Ars Pharmaceuticals Inc (SPRY) 最新ニュース
Insider Sell: Eric Karas Sells 25,000 Shares of ARS Pharmaceuticals Inc (SPRY) - GuruFocus
Ars Pharmaceuticals CLO Alexander Fitzpatrick sells $33,550 in stock - Investing.com UK
Ars Pharmaceuticals CLO Alexander Fitzpatrick sells $33,550 in stock By Investing.com - Investing.com Nigeria
ARS Pharmaceuticals CCO Eric Karas sells $250,000 in stock - Investing.com
ARS Pharmaceuticals CCO Eric Karas sells $250,000 in stock By Investing.com - Investing.com India
ARS Pharmaceuticals (SPRY) legal chief sells 3,355 shares in planned trade - Stock Titan
[144] ARS Pharmaceuticals, Inc. SEC Filing - Stock Titan
SPRY Should I Buy - Intellectia AI
From Clinical To Market: Managing Pharma's Most Challenging Transition - Life Science Leader
How The Evolving Story For ARS Pharmaceuticals (SPRY) Could Shape Future Valuation - Yahoo Finance
ARS Pharmaceuticals, Inc. (SPRY) soars 7.1%: Is further upside left in the stock? - MSN
(SPRY) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Drew Brees Collaborates with ARS Pharmaceuticals to Raise Awareness About Living Life with Severe Allergies - The Manila Times
SPRY Technical Analysis | Trend, Signals & Chart Patterns | ARS PHARMACEUTICALS INC (NASDAQ:SPRY) - ChartMill
Food Allergy Market Expected to Experience Accelerated Growth - openPR.com
[Form 3] ARS Pharmaceuticals, Inc. Initial Statement of Beneficial Ownership - Stock Titan
Food Allergy Market Expected to Experience Accelerated Growth and Market Evolution by 2036 – DelveInsight | Novartis, Roche, ARS Pharma, ALK Abelló, Alfresa Pharma, Stallergenes Greer, DBV Techno - Barchart.com
ARS Pharmaceuticals Hits Day High with 10.59% Surge in Stock Price - Markets Mojo
Cantor Fitzgerald raises ARS Pharmaceuticals stock price target on CSU program potential By Investing.com - Investing.com South Africa
Cantor Fitzgerald raises ARS Pharmaceuticals stock price target on CSU program potential - Investing.com India
ARS Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald - Moomoo
Liquidity Mapping Around (SPRY) Price Events - Stock Traders Daily
Creek Drive Management Group LLC's ARS Pharmaceuticals Inc(SPRY) Holding History - GuruFocus
Number of shareholders of ARS Pharmaceuticals, Inc. – NASDAQ:SPRY - TradingView
SPRY Stock Price, Quote & Chart | ARS PHARMACEUTICALS INC (NASDAQ:SPRY) - ChartMill
Ars Pharmaceuticals’ Earnings Call Highlights Growth and Risks - TipRanks
ARS Pharmaceuticals: Still A Buy As Neffy Access Improves (NASDAQ:SPRY) - Seeking Alpha
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q1 2026 Earnings Call Transcript - Insider Monkey
ARS Pharmaceuticals gears up for Q1 print; here are the recent forecast changes from Wall Street's most accurate analysts - MSN
ARS Pharma (SPRY) Q1 2026 Earnings Transcript - AOL.com
Why (SPRY) Price Action Is Critical for Tactical Trading - Stock Traders Daily
ARS Pharmaceuticals, Inc. (SPRY) reports Q1 loss, beats revenue estimates - MSN
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by ARS Investment Partners LLC - MarketBeat
ARS Pharmaceuticals Q1 earnings call highlights - MSN
Analysts Offer Insights on Healthcare Companies: RenovoRx (RNXT), Neurogene (NGNE) and ARS Pharmaceuticals (SPRY) - The Globe and Mail
ARS Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
SPRY SEC FilingsARS Pharms 10-K, 10-Q, 8-K Forms - Stock Titan
ARS Pharmaceuticals Q1 2026 Results: neffy® Drives $22.7M Revenue, U.S. and Global Expansion Updates - Minichart
Ars Pharmaceuticals anticipates CVS Caremark decision as it expands $199 retail access program - MSN
Transcript : ARS Pharmaceuticals, Inc., Q1 2026 Earnings Call, May 15, 2026 - marketscreener.com
ARS Pharmaceuticals Q1 2026 Earnings Call Transcript - MarketBeat
ARS Pharmaceuticals Inc (SPRY) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
ARS Pharma (SPRY) Q4 2025 Earnings Transcript - The Globe and Mail
ARS Pharmaceuticals 2026 Q1 10-Q: Financial Results, neffy™ Commercialization, and Key Risk Factors - Minichart
Rubric Capital (SPRY) reports 8.06% stake; 8,000,000 shares disclosed - Stock Titan
EX-99.1 - SEC.gov
ARS Pharmaceuticals Q1 Earnings Call Highlights - MarketBeat
SPRY: Q1 revenue hit $22.7M as neffy adoption surged, with expanded access set to drive further growth - TradingView
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):